After announcing a couple of new patents, electroCore Inc. (NASD: ECOR) increased 14.84% to $0.3273 in after-hours trading on Wednesday.
How many patents has ECOR disclosed?
The following patents were awarded to electroCore (ECOR) in connection with their non-invasive vagus nerve stimulation (nVNS) technology by the United States Patent and Trademark Office (USPTO):
- On November 29, 2022, the United States Patent Office issued U.S. Patent No. 11,511,109, titled “Non-invasive Magnetic or Electrical Nerve Stimulation to Treat Gastroparesis, Functional Dyspepsia, and Other Functional Gastrointestinal Disorders.” This patent covers techniques for using nVNS to treat gastroparesis, functional dyspepsia, and/or ileus. One of electroCore’s procedures involves passing an electrical current with a frequency between 1 kHz and 20 kHz via a patient’s outer skin surface (both the ear and/or the neck).
- On December 6, 2022, U.S. Patent No. 11,517,742, titled “Non-invasive Vagal Nerve Stimulation to Treat Disorders,” was granted. The basic focus of this ECOR patent is on tools and procedures for treating any problem in a patient with nVNS utilizing an electric current with a frequency of roughly 1 kHz to roughly 10 kHz and a duty cycle of roughly 1% to roughly 10%.
In Belgium, ECOR executed an identical effort:
Last month, ECOR revealed that Belgium has assigned a National Code Number (CNK) to its gammaCore Sapphire. The Belgian Pharmaceutical Association (APB) assigns CNK numbers, which are distinctive product code identities that enable product recognition across the whole pharmaceutical network, to items and medications that are commercially accessible from pharmacies throughout Belgium.
With the help of this good news, ECOR will be able to give patients a simple method to get gammaCore at their neighborhood drugstore. When it comes to making its therapy more broadly accessible across Europe, ECOR has made significant progress. GammaCore is now recognized in the Belgian pharmaceutical database and accessible through any pharmacy in Belgium as a result of the publishing of the CNK code.
How can the latest patents aid ECOR’s expansion?
The granting of these two additional patents expands and fortifies the use of ECOR’s nVNS treatment across several indications and techniques. The company is now better positioned to investigate the potential of nVNS for disorders other than migraines and cluster headaches as a result of the increase of its patent portfolio, which will enable ECOR to keep developing its potent technology.